Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents.

ABSTRACT: Immunotherapy has recently emerged as a novel strategy for treating different types of solid tumors, with promising results. However, still a large fraction of patients do not primarily respond to such approaches, and even responders sooner or later develop resistance. Moreover, immunotherapy is a promising strategy for certain malignancies but not for others, with this discrepancy having been attributed to a more immunogenic microenvironment of some tumors. As abnormal and augmented tumor vessels often occur in cancerogenesis, anti-angiogenic drugs have already demonstrated their effectiveness both in preclinical and in clinical settings. By targeting abnormal formation of tumor vessels, anti-angiogenetic agents potentially result in an enhanced infiltration of immune effector cells. More

SUBMITTER: Ciciola P 

PROVIDER: S-EPMC7141336 | biostudies-literature | 2020 Mar

REPOSITORIES: biostudies-literature